CIK 0001830487 · Large accelerated filer
Pharvaris N.V.
Sign in to watch- Ticker
- PHVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- other
- Phone
- 31 (0)71 203 6410
- Business address
- J.H. OORTWEG 21, 2333 CH LEIDEN, LEIDEN, Netherlands
- Former names
- Pharvaris, B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,335,217
- in 16 filings, $4.1M under 10b5-1 plans
Net −$20,335,217. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Schikan Johannes Gerardus Christiaan Petrus −$7.0M Director sold 64% of stake
- Lu Peng −$4.7M President sold 67% of stake
- Bjork Elisabeth −$2.0M Director sold 78% of stake
- Lesage Anne −$1.9M Chief Early Development sold 40% of stake
- Abele Stefan Andreas −$1.8M Chief Technical Ops Officer sold 54% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-17 | Bjork Elisabeth Director | Option exercise | +17,500 | $18.14 | $317K | 67,667 |
| 2026-09-17 | Bjork Elisabeth Director | Sale | −52,500 | $37.89 | $2.0M | 15,167 |
| 2026-09-17 | Bjork Elisabeth Director | Option exercise · Stock Option (Right to Buy) | −35,000 | 0 | ||
| 2026-09-17 | Bjork Elisabeth Director | Option exercise · Stock Option (Right to Buy) | −17,500 | 0 | ||
| 2026-09-17 | Glassman Robert Director | Option exercise | +14,493 | $18.14 | $263K | 24,993 |
| 2026-09-17 | Glassman Robert Director | Sale | −14,493 | $38.56 | $559K | 10,500 |
| 2026-09-17 | Glassman Robert Director | Option exercise · Stock Option (Right to Buy) | −14,493 | 0 | ||
| 2026-09-17 | Lesage Anne Chief Early Development | Sale | −20,000 | $38.27 | $765K | 73,969 |
| 2026-09-17 | Modig Berndt Chief Executive Officer | Option exercise | −300,000 | $35.00 | $10.5M | 650,000 |
| 2026-09-15 | Abele Stefan Andreas Chief Technical Ops Officer | Option exercise | +45,000 | $16.40 | $738K | 85,468 |
| 2026-09-15 | Abele Stefan Andreas Chief Technical Ops Officer | Sale | −45,000 | $38.14 | $1.7M | 40,468 |
| 2026-09-15 | Abele Stefan Andreas Chief Technical Ops Officer | Sale | −1,400 | $39.24 | $55K | 39,068 |
| 2026-09-15 | Abele Stefan Andreas Chief Technical Ops Officer | Option exercise · Stock Option (Right to Buy) | −45,000 | 44,500 | ||
| 2026-09-15 | Glassman Robert Director | Option exercise 10b5-1 | +8,667 | $22.31 | $193K | 19,167 |
| 2026-09-15 | Glassman Robert Director | Sale 10b5-1 | −8,667 | $38.27 | $332K | 10,500 |
| 2026-09-15 | Glassman Robert Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,667 | 0 | ||
| 2026-09-15 | Souverijns Wim Chief Commercial Officer | Sale 10b5-1 | −6,090 | $38.99 | $237K | 39,021 |
| 2026-09-14 | Souverijns Wim Chief Commercial Officer | Option exercise 10b5-1 | +20,000 | $17.43 | $349K | 65,111 |
| 2026-09-14 | Souverijns Wim Chief Commercial Officer | Sale 10b5-1 | −20,000 | $39.31 | $786K | 45,111 |
| 2026-09-14 | Souverijns Wim Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 95,000 |
Page 2 of 9 · 170 trades